Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: Subgroup analysis from CALGB 19901 and CALGB 10101

Leukemia and Lymphoma

Volumn 54, Issue 12, 2013, Pages 2654-2659

  Jones, Jeffrey A ^a   Ruppert, Amy S ^a   Zhao, Weiqiang ^a   Lin, Thomas S ^b   Rai, Kanti ^c   Peterson, Bercedis ^d   Larson, Richard A ^e   Marcucci, Guido ^a   Heerema, Nyla A ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Alemtuzumab; Clinical trial; CLL; Cytogenetics; Immunoglobulin genes

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HIGH RISK POPULATION; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; INTERPHASE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONSOLIDATION CHEMOTHERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; REMISSION INDUCTION;

EID: 84887249660     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.788179     Document Type: Article

References (16)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al . Addition of rituximab to fl udarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial . Lancet 2010 ; 376 : 1164-1174 .
2. Woyach JA, Ruppert AS, Heerema NA, et al . Chemoimmunotherapy with fl udarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 . J Clin Oncol 2011 ; 29 : 1349-1355 .
3. O' Brien S, Wierda W, et al . Long-term results of the fl udarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia . Blood 2008; 112: 975-980.
4. Byrd JC, Gribben JG, Peterson BL, et al . Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fl udarabine and rituximab in chronic lymphocytic leukemia: justifi cation for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443.
5. Zenz T, Mertens D, Kuppers R, et al . From pathogenesis to treatment of chronic lymphocytic leukaemia . Nat Rev Cancer 2010; 10: 37-50.
6. Grever MR, Lucas DM, Dewald GW, et al . Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799-804.
7. Montillo M, Tedeschi A, Miqueleiz S, et al . Alemtuzumab as consolidation after a response to fl udarabine is eff ective in purging residual disease in patients with chronic lymphocytic leukemia . J Clin Oncol 2006 ; 24 : 2337-2342 .
8. Schweighofer C D, R itgen M, E ichhorst B F, et a l. C onsolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in fi rst remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG) . Br J Haematol 2009 ; 144 : 95-98 .
9. Wendtner C M, R itgen M, S chweighofer C D, et a l. C onsolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in fi rst remission-experience on safety and effi cacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) . Leukemia 2004 ; 18 : 1093-1101 .
10. Lozanski G, H eerema N A, F linn I W, et a l. A lemtuzumab is an eff ective therapy for chronic lymphocytic leukemia with p53 mutations and deletions . Blood 2004 ; 103 : 3278-3281 .
11. Stilgenbauer S, Zenz T, Winkler D, et al . Subcutaneous alemtuzumab in fl udarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group . J Clin Oncol 2009 ; 27 : 3994-4001 .
12. Hillmen P, Skotnicki AB, Robak T, et al . Alemtuzumab compared with chlorambucil as fi rst-line therapy for chronic lymphocytic leukemia . J Clin Oncol 2007 ; 25 : 5616-5623 .
13. Byrd J C, P eterson B L, R ai K R, et a l. F ludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: fi nal report of Cancer and Leukemia Group B study 19901. Leuk Lymphoma 2009; 50: 1589-1596.
14. Lin T S, D onohue K A, B yrd J C, et a l. C onsolidation therapy with subcutaneous alemtuzumab after fl udarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: fi nal analysis of CALGB 10101 . J Clin Oncol 2010 ; 28 : 4500-4506 .
15. Cheson B D, B ennett J M, G rever M, et a l. N ational Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment . Blood 1996 ; 87 : 4990-4997 .
16. Dohner H, S tilgenbauer S, B enner A, et a l. G enomic aberrations and survival in chronic lymphocytic leukemia . N Engl J Med 2000 ; 343 : 1910-1916 .